Here are five other takeaways from the preliminary financial report:
- Fourth-quarter revenue, excluding COVID-19 testing, grew 28 percent compared to the same period last year.
- Including COVID-19 testing, revenue increased by 16 percent.
- COVID-19 testing revenue decreased by 87 percent with a reported $5.9 million in revenue.
- Screening revenue increased by 41 percent with an estimated revenue between $401.8 and $402.8 million, excluding the PreventionGenetics acquisition.
- Including the PreventionGenetics acquisition, screening revenue was up by 45 percent.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.